High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL

Blinatumomab is a bispecific T-cell engager approved for B-cell precursor acute lymphoblastic leukemia (B-ALL) with persistent minimal residual disease (MRD) or in relapse. The prognostic impact of tumor load has been suggested before other immunotherapies but remains poorly explored before blinatu...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Aurelie Cabannes-Hamy, Eolia Brissot, Thibaut Leguay, Francoise Huguet, Patrice Chevallier, Mathilde Hunault, Martine Escoffre-Barbe, Thomas Cluzeau, Marie Balsat, Stephanie Nguyen, Florence Pasquier, Magda Alexis, Veronique Lheritier, Cedric Pastoret, Eric Delabesse, Emmanuelle Clappier, Herve Dombret, Nicolas Boissel
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Ferrata Storti Foundation 2022-03-01
Цуврал:	Haematologica
Онлайн хандалт:	https://haematologica.org/article/view/10569
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!